Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Acute Myeloid Leukemia Induced by Therapy with a 24-Month Latency Following CD19 CAR-T Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Study

  • By

  • Manqi Su

  • Chentong Huang

  • Zhanna Zhang

  • Xiaoxia Wang

  • Panruo Jiang

  • Yiran Chen

  • Gongqiang Wu

  • August 14, 2026

Share

  • 1

    Therapy-related acute myeloid leukemia (t-AML) can develop as a late complication of CD19 CAR-T cell therapy, with a notable latency period.

  • 2

    A case study reported t-AML occurring 24 months after CD19 CAR-T therapy in a patient with relapsed/refractory diffuse large B-cell lymphoma.

  • 3

    Genomic monitoring revealed a transition from wild-type TP53 to biallelic loss of TP53 in the patient diagnosed with t-AML.

  • 4

    The patient achieved partial remission of t-AML after treatment with azacitidine and venetoclax, followed by allogeneic stem cell transplantation.

  • 5

    This case highlights the need for ongoing hematologic monitoring and genomic profiling beyond 12 months post-CAR-T therapy.

Original Source(s)

Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report

  • by Manqi Su, Chentong Huang, Zhanna Zhang, Xiaoxia Wang, Panruo Jiang, Yiran Chen, Gongqiang Wu

  • August 14, 2026

Related Content

Correction: Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer

National Cancer Institute–Supported Obesity and Cancer Research, 2015-2022